EyePoint Pharmaceuticals CEO and leadership

Official pSivida Corporate LinkedIn profile.Dr. Ashton was named the Company's President & Chief Executive Officer in January 2009 having previously served as Managing Director from January 2007 to January 2009 and Executive Director of Strategy from December 2005 to January 2007. Dr. Ashton was the President and Chief Executive Officer of Control Delivery Systems, Inc. from 1996 until its acquisition by pSivida in December 2005. CDS was a drug delivery company that Dr. Ashton co-founded in 1991. Prior to co-founding CDS, Dr. Ashton was a joint faculty member in the Departments of Ophthalmology and Surgery at the University of Kentucky, served on the faculty of Tufts University and worked as a pharmaceutical scientist at Hoffman-La-Roche. Dr. Ashton received a Bachelor of Science degree in chemistry from Durham University, England, and a Ph.D. in pharmaceutical science from the University of Wales.

Dr. Paggiarino joined EyePoint Pharmaceuticals from Lpath, a leader in lipid-targeted therapeutics, where he served as senior vice president and chief development officer. Prior to joining Lpath, he was vice president and therapeutic unit head for retina diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical development pipeline through regulatory approvals worldwide. Dr. Paggiarino previously served as executive director of clinical development and medical affairs at Pfizer Global R&D, with a focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases, and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career, he held research and development positions at Angelini Pharmaceuticals, a private company, where he advanced to president of the firm, and Pharmacia Global R&D, where he was clinical program director of ophthalmology with responsibilities including Xalatan®, one of the leading glaucoma therapies in the world. Dr. Paggiarino earned his degree in Medicine and General Surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.

Mr. Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly-traded and privately-held organizations. Mr. Elston most recently served as Chief Financial Officer and Head of Corporate Development at Enzyvant Therapeutics where he helped build the pre-commercial rare disease firm leading to its recent acquisition. He previously was President and Chief Executive Officer at 2X Oncology, Inc., where he advanced the Company from a spin-out into a multi-program, clinical-stage organization. He has also held senior executive roles at Juniper Pharmaceuticals, Inc. KBI Biopharma and Optherion, Inc. Mr. Elston began his career in public accounting at PriceWaterhouseCoopers. He earned his B.B.A. in accounting from Pace University and is a Certified Public Accountant. He currently serves as a Trustee and Audit Committee Chairman of the DWS - DBX ETF Trust.

Ms. Lefebvre was Vice-President, Head of Regulatory Science at Hengrui USA where she was responsible for overseeing U.S. and E.U. regulatory strategies for clinical programs in various phases of development. Previously, she spent 10 years at Bausch Health Companies Inc. where she held roles of increasing responsibility and led the successful approvals of two ocular drug products, LOTEMAX gel and VYZULTA®. Earlier in her career, Ms. Lefebvre held senior roles in regulatory strategy and affairs at Lundbeck Inc., Alpharma Pharmaceuticals, Bristol-Myers Squibb, and Societe D’Analyses Biopharmaceutiques Inc. Ms. Lefebvre holds a B.S. in Biochemistry from the University of Montreal and an M.S. in Regulatory Affairs from Northeastern University.

The Director of the New England Eye Center, Dr Jay Duker brings more than 30 years of ophthalmology experience to EyePoint with roles held in the clinical, research, and academic settings.

Ms. Leonard currently serves as the Chief People Officer and SVP, IT. She brings to EyePoint over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management, and culture development experience. Most recently Ms. Leonard served as the Head of HR, Consumer Healthcare, and Global Functions for Sanofi, US. From 2012 to 2015, Ms. Leonard served as the Senior Vice President of HR & IT of PDI, Inc., a NASDAQ-listed healthcare commercialization company now named Interpace Diagnostics Group, Inc.

Ms. Leonard holds a Master's Degree in Organizational Development and Human Resources from The University of San Francisco, and a B. A. in Psychology and Business Administration from The University of California at Los Angeles (UCLA.) Ms. Leonard is a Certified Professional Coach and has earned her Associate Certified Coach (ACC) from the International Coaching Federation (ICF.) She is also certified in the Hogan Assessment Certified Consultant.

Michael Pine is a Chief Corporate Development & Strategy Officer at EYEPOINT PHARMACEUTICALS, INC. and is based in New, York. He attended Columbia Business School between 1999 and 2001.

Said Saim is a Chief Technology Officer at EYEPOINT PHARMACEUTICALS, INC. and Senior Dir:Pharmaceutical Dev at COLLEGIUM PHARMACEUTICAL, INC and is based in Watertown Town, Massachusetts. He has worked as Research Engineer at ABC Laboratories, Senior Principal Scientist at BOEHRINGER INGELHEIM, and Assistant Research Professor at Higuchi Biosciences Center. Said attended University of Kansas between 1987 and 1990.

Scott Jones is a Chief Commercial Oficer at EYEPOINT PHARMACEUTICALS, INC. and is based in New York City, New York. He works or has worked as Chief Commercial Officer at NotalVision Inc. Scott studied at University of Florida between 1992 and 1995.